Safety and Efficacy of Anti-BCMA-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MM

This study is testing a CAR-T cell therapy targeting two proteins (BCMA and GPRC5D) found on myeloma cells, for people with relapsed or hard-to-treat multiple myeloma who have already tried multiple prior treatments including at least one proteasome inhibitor, one immunomodulatory drug, and one anti-CD38 antibody. **You may be eligible if...** - You are between 18 and 75 years old with a confirmed diagnosis of multiple myeloma - Your disease has relapsed or is refractory after at least 3 prior lines of therapy - You have measurable disease (detectable M-protein, free light chains, or related markers) - Your physical performance is adequate - Your organ function meets the required thresholds **You may NOT be eligible if...** - You have not failed at least 3 prior treatment lines - You have severe uncontrolled infection - You have significant heart, liver, kidney, or lung problems - You are pregnant or breastfeeding - You are currently enrolled in another clinical trial Talk to your doctor to see if this trial is right for you.